ADVA
6.5.2021 09:02:06 CEST | Business Wire | Press release
ADVA (FSE: ADV) today announced that its FSP 3000 open line system (OLS) played a key role in a demo showcasing a real-time public safety application. In the METRO-HAUL field trial, AI-based thermal-imaging and pan-tilt-zoom video cameras were used to secure a surveillance area. Advanced video analytics and active camera control require the transport of high-bandwidth video and latency-critical control traffic to a remote control center. Using the ADVA FSP 3000 OLS with flexible micro-ROADMs as well as QuadFlex™ transponders, the demo featured a programmable metro network with edge nodes for time-critical computing. Conducted at Fraunhofer HHI’s test beds in Berlin as part of the 5G Infrastructure Public Private Partnership (5G PPP) initiative’s METRO-HAUL project, the trial involved ADVA and several research center and university partners.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210506005044/en/
“This METRO-HAUL demo reveals how modern metro networks with edge compute and storage functionality can support intelligent video surveillance systems to provide unprecedented power and efficiency. It also highlights how important network slicing will be in enabling the agile resource allocation needed to support high-bandwidth, ultra-low-latency applications such as automated object detection and tracking,” said Achim Autenrieth, director, advanced technology, ADVA. “Built on our FSP 3000 OLS with flexible micro-ROADMs and SDN control, this showcase highlights just how much operators can now achieve by deploying disaggregated 5G infrastructure with edge computing and network slicing capabilities. It illustrates that next-generation metro networks are ready to support a new breed of high-bandwidth, low-latency applications and take safety surveillance technology to the next stage.”
In the METRO-HAUL field trial, application-aware network slicing was used for prioritized transport of critical real-time video streams. Object tracking was performed by a video management and analytics service running locally as a virtual network function, and instantiated ad-hoc on an edge-compute-enabled metro node. The demo showed a high-definition video stream automatically tracing any object crossing the perimeter of the surveillance zone. The stream was then distributed to a central location for real-time analysis and remote incident control. Managed by ADVA’s Ensemble Controller with its proven SDN domain controller, the test network enabled rapid provisioning of high-bandwidth resources and offered end-to-end latency awareness. Flexible connectivity was provided by coherent transponders and an innovative ROADM-based OLS architecture optimized for metro network demands. The demo was selected as one of the Top 10 5G PPP Infrastructure Trials and Pilots.
“Alongside partners like ADVA, we’ve been working to rapidly develop transport network slicing and open the door to a world of new applications. Enabling multi-access edge computing right where it’s needed will be key to many emerging use cases. This METRO-HAUL field trial harnessing ADVA’s open transport technology shows how it’s now possible to create flexible end-to-end architectures that interface with both 5G access and multi-Tbit elastic core networks,” said Andrew Lord, senior manager, optical research, BT. “Right now, digitalization and 5G are transforming nearly every industry, and the impact on public safety technology will be hugely significant. As ADVA’s showcase proves, tomorrow’s networks will take speed, low latency, reliability and agility to the next level, enabling mission-critical security services to process, store and analyze more data and deliver more value than ever before.”
The results from the demo will be presented at the OFC 2021 technical conference on Friday, June 11 at 11 a.m. (PDT), Session ID - F4H.2: https://adva.li/ofc21-latency-aware-demo .
About ADVA
ADVA is a company founded on innovation and focused on helping our customers succeed. Our technology forms the building blocks of a shared digital future and empowers networks across the globe. We’re continually developing breakthrough hardware and software that leads the networking industry and creates new business opportunities. It’s these open connectivity solutions that enable our customers to deliver the cloud and mobile services that are vital to today’s society and for imagining new tomorrows. Together, we’re building a truly connected and sustainable future. For more information on how we can help you, please visit us at www.adva.com .
Published by:
ADVA Optical Networking SE, Munich, Germany
www.adva.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20210506005044/en/
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Zambon Announces European Commission Approval of Hopledo® for Adults with Parkinson's Disease and Moderate to Severe Motor Fluctuations28.8.2026 11:00:00 CEST | Press release
Hopledo® is a first-in-class, oral, modified-release formulation of levodopa/carbidopa (LD/CD) approved for the treatment of motor fluctuations of Parkinson’s disease Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026 The approval is based on data from the Phase 3 RISE-PD trial where Hopledo® demonstrated a significant increase in Good ON time compared with immediate-release LD/CD with fewer daily doses and a comparable safety profile Zambon today announced that the European Commission (EC) has granted marketing authorization for Hopledo® (modified-release levodopa/carbidopa) for the treatment of adult patients with Parkinson’s disease and moderate to severe motor fluctuations who have not been sufficiently stabilized with oral levodopa/dopa decarboxylase (DDC) inhibitor-based treatment regimens. Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026. The company is working closely
MTG-I2 Safely in Orbit, Unlocking Faster and Sharper Weather Monitoring Across Europe28.8.2026 10:16:00 CEST | Press release
The Meteosat Third Generation Imager 2 satellite (MTG-I2) has successfully passed its first critical post-launch milestones, completing the first full Meteosat Third Generation constellation in orbit. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828243790/en/ Credit: Arianespace livestream The imager satellite MTG-I2 is safely in orbit and operating as expected following its successful launch yesterday at 22:11 CEST on board an Ariane 6 rocket from Europe’s Spaceport in French Guiana. Our teams have established communication with the spacecraft, which has also deployed its solar panels to ensure its autonomous production of energy. MTG-I2 is in perfect shape to start its Launch and Early Operations Phase that will bring it to a higher orbit, 36 000km above Earth over the following two weeks, where a longer period of calibration and validation of its instruments will begin. This summer’s extreme weather and wildfires hav
New Daiichi Sankyo Data Underscore the Effect of Bempedoic Acid in the Real-World Management of Dyslipidemia and Cardiovascular risk28.8.2026 10:00:00 CEST | Press release
Analyses from the multinational MILOS study show that LDL-C reductions achieved with up to one year of treatment with bempedoic acid-containing therapies translate to a 17.1% relative reduction and a 4.8% absolute reduction in predicted 10-year cardiovascular risk.1 Real-world data demonstrated clinically relevant mean LDL-C reductions of at least 24.9%, regardless of patient gender or glycaemic status, after one year of follow-up.2,3 Findings presented at ESC Congress 2026 reinforce the clinical value of bempedoic acid in routine clinical practice, and demonstrate the continued investment of Daiichi Sankyo in addressing outstanding unmet needs in cardiovascular disease (CVD). Daiichi Sankyo (TSE:4568) today announced new results from the MILOS study that demonstrate the real-world impact of bempedoic acid administered either alone or as a fixed-dose combination with ezetimibe, in the management of dyslipidaemia. Presented at the European Society of Cardiology Congress 2026 in Munich,
TVS Motor Company Appoints Peyman Kargar as Director and Chief Executive Officer28.8.2026 09:31:00 CEST | Press release
Peyman Kargar appointed Director and Chief Executive Officer of TVS Motor Company, effective January 27, 2027 K. N. Radhakrishnan to continue as Director and Chief Executive Officer until then and subsequently will serve as Non-Executive Director up to the date of the ensuing AGM scheduled in July 2027 Appointment supports TVS Motor Company's next phase of growth and innovation TVS Motor Company, part of TVS VENU and a leading global manufacturer of two and three-wheelers, today announced the appointment of Peyman Kargar as Director and Chief Executive Officer, effective January 27, 2027. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260827012301/en/ Peyman Kargar Peyman will succeed K. N. Radhakrishnan, who will continue in his role until then to ensure a seamless transition. Following the transition, Radhakrishnan will serve as Non-Executive Director up to the date of the ensuing AGM scheduled in July 2027. He has been a
Philips and Imricor Launch Cardiac Interventional MR Lab Solution, Expanding Longstanding Collaboration27.8.2026 21:27:00 CEST | Press release
Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, and Imricor Medical Systems (ASX: IMR), a pioneer and world-leading developer of MR-compatible products for interventional MR procedures, today announced a new Interventional MR (iMR) lab solution for Philips 1.5T MR. The first commercially available configuration* combines Philips’ 1.5T MRI platform and Imricor's portfolio of iMR systems and consumables, enabling an MR-guided workflow for cardiac intervention, without compromising on MR field strength. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260827693715/en/ Meeting the need for greater tissue insight during cardiac intervention Cardiac arrhythmias affect millions of people worldwide, and catheter ablation is an established and increasingly utilized treatment for many complex cardiac arrhythmias. Yet today, these procedures continue to rely primarily on X-ray fluoroscopy, which provides only
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom